Compare Gilead Sciences, Inc. (GILD) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Halliburton Company — how do they compare? Gilead Sciences, Inc. trades at $136.55 (market cap $163.51B), while Halliburton Company trades at $35.29 (market cap $29.45B). The key difference: Gilead Sciences, Inc. is far larger — about 5.6× Halliburton Company's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | HAL | |
|---|---|---|
Market Cap | $163.51B | $29.45B |
Sector | Health | Energy |
52-Week High | $155.80 | $42.98 |
52-Week Low | $108.22 | $20.50 |
Enterprise Value | $178.05B | $35.53B |
Dividend Yield | 2.49% | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Halliburton (HAL) trades at $34.99, down 1.21% on the day, with a bullish technical signal from moving averages and recent contract wins boosting sentiment. The company shows solid profitability with a 6.95% net income margin and 14.56% ROE, though 2025 revenue dipped to $22.18B. Earnings have beaten estimates for three consecutive quarters, with Q2 2026 results pending. Cash flow trends are mixed, with 2025 net cash flow negative at -$412M despite strong operational cash generation.
The outlook remains positive with a consensus price target of $44.78, implying 28% upside, supported by 71% analyst buy ratings. Key risks include oil price volatility and execution challenges from new contracts. The stock's current valuation at a P/E of 19.48 appears reasonable relative to growth prospects, but investors should monitor debt levels and global energy demand shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
